Lexicon Pharmaceuticals (LXRX) Accumulated Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Accumulated Expenses data on file, last reported at $6.9 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 46.69% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 46.69% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, down 56.68% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.9 million, down from $13.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for LXRX reached as high as $30.4 million in Q4 2024 and fell as low as $6.9 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $14.4 million across 5 years, with a median of $13.2 million in 2025.
• Across the five-year window, Accumulated Expenses tumbled 57.23% in 2022 and soared 124.27% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $12.8 million in 2022, then jumped by 34.28% to $17.2 million in 2023, then surged by 77.46% to $30.4 million in 2024, then slumped by 56.68% to $13.2 million in 2025, then tumbled by 47.67% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $6.9 million in Q1 2026, $13.2 million in Q4 2025, and $13.6 million in Q3 2025.